MOLN - Molecular Partners confirms retained activity of ensovibep on positions mutated in Omicron

Molecular Partners (NASDAQ:MOLN) has issued a statement regarding the recently identified SARS-CoV-2 variant, termed Omicron (B.1.1.529). Ensovibep has been consistently tested in vitro against all existing and potential variants of concerns, and its retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concern. Testing has been initiated in order to confirm the potency of ensovibep against the full Omicron pseudotype virus, with results expected in the coming weeks. Global Phase 2-3 EMPATHY clinical study in COVID-19 ongoing with topline phase 2 data available in early 2022.

For further details see:

Molecular Partners confirms retained activity of ensovibep on positions mutated in Omicron